The role of dinutuximab beta with beta cell function, apoptosis, and proliferation: new approaches to proteomic analysis of insulinoma [0.03%]
关于dinutuximab beta与β细胞功能、凋亡及增殖的作用：胰岛素瘤蛋白质组分析的新方法
Ayse Karatug Kacar
Ayse Karatug Kacar
The aim of this study was to investigate gene expressions related to beta cell function, and the altered protein profiles in insulinoma INS-1 cells following DB application, under both cytotoxic and non-cytotoxic conditions, with a focus on...
Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cells [0.03%]
SR59230A（肾上腺素受体拮抗剂）与常用化疗药物及靶向治疗药物联用的协同作用：癌细胞和内皮细胞研究
Arianna Bandini,Letizia Biso,Cristina Viaggi et al.
Arianna Bandini et al.
β3-adrenergic receptors (β3-ARs) are increasingly recognized as modulators of tumor progression and treatment resistance across multiple cancer types. SR59230A, a β3-AR antagonist, has shown preclinical antitumor activity through mechani...
Evaluation of the anti-leukemia activity and underlying mechanisms of the novel perinucleolar compartment inhibitor CTI-2 in acute myeloid leukemia [0.03%]
评估新型核仁旁区抑制剂CTI-2在急性髓系白血病中的抗白血病活性及作用机制
Anran Li,Mingmin Yu,Yue Zhao et al.
Anran Li et al.
Acute myeloid leukemia (AML) is a malignant clonal hematological tumor originating from immature myeloid cells and is the most prevalent type of leukemia in adults. Traditional chemotherapy regimens based on cytarabine and anthracycline age...
Rucaparib induces mitochondrial fragmentation and apoptosis in prostate cancer cells by targeting Drp1 [0.03%]
鲁卡帕尼通过靶向Drp1诱导前列腺癌细胞线粒体分裂和凋亡
Xiaodong Lu,Yishu Lin,Hao Tang et al.
Xiaodong Lu et al.
Mitochondrial dynamics, particularly the balance between fission and fusion, are critical in regulating cellular metabolism, apoptosis, and cancer progression. Dysregulation of this balance contributes to tumor survival and therapeutic resi...
Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors [0.03%]
Lurbinectedin联合伊立替康治疗晚期实体瘤的I期疗效、安全性和药代动力学研究结果
Alejandro Falcón,Santiago Ponce,Gregory M Cote et al.
Alejandro Falcón et al.
Lurbinectedin and irinotecan showed synergistic antitumor activity when combined in preclinical studies, and have non-completely overlapping toxicity profiles. A two-stage phase I/II trial was designed to evaluate the combination. The first...
Comparative analysis of the effects of PSPH and PHGDH inhibitors on tumor cell proliferation [0.03%]
PSPH和PHGDH抑制剂对肿瘤细胞增殖影响的比较分析
Yanbing Wang,Longze Sha
Yanbing Wang
Serine metabolism plays a pivotal role in supporting the rapid proliferation of tumor cells, with PHGDH recognized as a key rate-limiting enzyme and therapeutic target. However, whether its antitumor effects rely exclusively on serine metab...
Association of different approvals with Chinese Society of Clinical Oncology recommendation levels for solid tumor drugs: a cross-sectional analysis [0.03%]
中国临床肿瘤学会分期指南与固有肿瘤药物适应症获批范围的关联性分析：横断面研究
Lirong Zhang,Hongbin Yi,Liping Kuai et al.
Lirong Zhang et al.
In China, many solid tumor drugs have been approved via the accelerated approval (AA) pathway. We extracted data regarding indications for solid tumor-treating drugs approved by the National Medical Products Administration (NMPA) between 20...
Targeting the Keap1/Nrf2 axis in cancer: molecular mechanisms and pharmacological interventions [0.03%]
靶向癌细胞中Keap1/Nrf2轴：分子机制与药理学干预措施
Yangchen Xia,Ziyang Xu,Xun Yuan et al.
Yangchen Xia et al.
The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) is the first-line regulator of a plethora of cytoprotective pathways, such as inflammation, redox metabolism, and proteostasis. Besides its protective role in oxida...
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes [0.03%]
关于Talazoparib联合替莫唑胺治疗无DNA修复基因突变的转移性去势抵抗性前列腺癌患者的Ib/II期临床研究
Karen A Autio,Christos E Kyriakopoulos,Paul Palyca et al.
Karen A Autio et al.
As monotherapy, PARP inhibitors have little cytotoxic effect in tumors without homologous recombinant repair (HRR) alterations. Supported by preclinical models, we hypothesized that the PARP inhibitor talazoparib in combination with temozol...
Targeting the TRIB3-MYC axis in cancer: mechanistic insights and therapeutic disruption strategies [0.03%]
靶向癌症中的TRIB3-MYC轴：机制见解和治疗干扰策略
Emadeldin M Kamel,Sulaiman A Alsalamah,Ahmed A Allam et al.
Emadeldin M Kamel et al.
The oncogenic transcription factor MYC drives proliferation, metabolism, and therapy resistance in the majority of human cancers, yet its large, nuclear protein-protein interface has long frustrated direct drug discovery. A pivotal breakthr...